Advertisement

Journal of Neuro-Oncology

, Volume 121, Issue 3, pp 499–504 | Cite as

VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab

  • Anna Luisa Di Stefano
  • Marianne Labussiere
  • Giuseppe Lombardi
  • Marica Eoli
  • Donata Bianchessi
  • Francesco Pasqualetti
  • Patrizia Farina
  • Stefania Cuzzubbo
  • Jaime Gallego-Perez-Larraya
  • Blandine Boisselier
  • Francois Ducray
  • Caroline Cheneau
  • Arrigo Moglia
  • Gaetano Finocchiaro
  • Yannick Marie
  • Amithys Rahimian
  • Khe Hoang-Xuan
  • Jean Yves Delattre
  • Karima Mokhtari
  • Marc SansonEmail author
Laboratory Investigation

Abstract

Although anti-VEGF therapy is widely used in high-grade gliomas, no predictor of response or toxicity has been reported yet. We investigated here the association of the functional single nucleotide polymorphism (SNP) rs2010963, located in the 5′ untranslated terminal region of the VEGFA gene, with survival, response to bevacizumab (BVZ) and vascular toxicity. The rs2010963 was genotyped by Taqman assay in blood DNA from 954 glioma patients with available survival data, including 225 glioblastoma (GBM) patients treated with BVZ. VEGFA plasma levels were assessed by ELISA in 87 patients before treatment. Thrombo-hemorragic adverse events were recorded during BVZ treatment or not, and in an independent population of 92 GBM patients treated with temozolomide. The CC genotype was associated with the occurrence of thrombo-hemorragic events (CC 25 versus CG 13.5 and GG 5.2 %; P = 0.0044) during BVZ. A similar but weaker and non significant trend was observed in patients not receiving BVZ. A CC genotype was associated with higher levels of plasma VEGFA at baseline (107.6 versus 57.50 pg/mL in heterozygotes (CG) and 52.75 pg/mL in GG patients, P = 0.035 and P = 0.028 respectively). The CC genotype tended to be associated to longer PFS when treated with BVZ (P = 0.05), but not when treated with the temozolomide treatment. Our data suggest that the rs2010963 genotype is associated with longer PFS, higher risk of vascular events in recurrent GBM especially treated with BVZ, and higher plasma VEGFA concentration. It may help to identify patients at risk of vascular adverse events during BVZ treatment.

Keywords

Glioblastoma VEGF Bevacizumab SNP rs2010963 

Abbreviations

VEGFA

(Vascular endothelial factor A)

OS

(Overall survival)

PFS

(Progression free survival)

W.H.O.

(World Health Organization)

KPS

(Karnofsky performance status)

SNP

(Single nucleotide polymorphism)

Notes

Acknowledgments

Work supported by a Grant from the Institut National du Cancer (INCa; Angiogli- RAFc0209). A.L. Di Stefano received an investigator fellowship from PRIN 2010ZESJWN_008. The research leading to these results has received funding from the program “investissements d’avenir” ANR-10-IAIHU-06. The authors are indebted to Alexandru Agachi for English Editing.

Conflict of interest

None.

Supplementary material

11060_2014_1677_MOESM1_ESM.doc (124 kb)
Supplementary material 1 (DOC 124 kb)

References

  1. 1.
    Kunnakkat S, Narayana A (2011) Bevacizumab in the treatment of high-grade gliomas: an overview. Angiogenesis 14:423–430PubMedCrossRefGoogle Scholar
  2. 2.
    Jensen RL (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49:189–195; discussion 196Google Scholar
  3. 3.
    Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740PubMedCrossRefGoogle Scholar
  4. 4.
    Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729PubMedCrossRefGoogle Scholar
  6. 6.
    Gil MJ, de Penas Las R, Reynes G et al (2012) Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish neuro-oncology research group (GEINO). Anticancer Drugs 23:659–665PubMedCrossRefGoogle Scholar
  7. 7.
    GKB P. http://www.pharmgkb.org/ [online]. Available at: http://www.pharmgkb.org/
  8. 8.
    Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245–1249PubMedCrossRefGoogle Scholar
  9. 9.
    Tischer E, Mitchell R, Hartman T et al (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954PubMedGoogle Scholar
  10. 10.
    Minchenko A, Salceda S, Bauer T, Caro J (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40:35–39PubMedGoogle Scholar
  11. 11.
    Schultz A, Lavie L, Hochberg I et al (1999) Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100:547–552PubMedCrossRefGoogle Scholar
  12. 12.
    Jain L, Vargo CA, Danesi R et al (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8:2496–2508PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235PubMedCrossRefGoogle Scholar
  14. 14.
    Zhai R, Liu G, Zhou W et al (2008) Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 14:612–617PubMedCrossRefGoogle Scholar
  15. 15.
    Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L (2006) Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 35:21–28PubMedCrossRefGoogle Scholar
  16. 16.
    Li R, Zhao Y, Fan W et al (2011) Possible association between polymorphisms of human vascular endothelial growth factor a gene and susceptibility to glioma in a Chinese population. Int J Cancer 128:166–175PubMedCrossRefGoogle Scholar
  17. 17.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  18. 18.
    Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972PubMedCrossRefGoogle Scholar
  19. 19.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Petrovic D, Verhovec R, Globocnik Petrovic M, Osredkar J, Peterlin B (2007) Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 107:291–295PubMedCrossRefGoogle Scholar
  21. 21.
    Awata T, Inoue K, Kurihara S et al (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639PubMedCrossRefGoogle Scholar
  22. 22.
    Inoue M, Itoh H, Ueda M et al (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108–2116PubMedCrossRefGoogle Scholar
  23. 23.
    Petrovic MG, Korosec P, Kosnik M et al (2008) Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis 14:1382–1387PubMedCentralPubMedGoogle Scholar
  24. 24.
    van der Meer P, De Boer RA, White HL et al (2005) The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail 11:279–284PubMedCrossRefGoogle Scholar
  25. 25.
    Vailati FB, Crispim D, Sortica DA, Souza BM, Brondani LA, Canani LH (2012) The C allele of -634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue. Invest Ophthalmol Vis Sci 53:6411–6415PubMedCrossRefGoogle Scholar
  26. 26.
    Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285PubMedCrossRefGoogle Scholar
  27. 27.
    Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79:27–38PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Anna Luisa Di Stefano
    • 1
    • 2
    • 3
  • Marianne Labussiere
    • 1
  • Giuseppe Lombardi
    • 4
  • Marica Eoli
    • 5
  • Donata Bianchessi
    • 5
  • Francesco Pasqualetti
    • 6
  • Patrizia Farina
    • 2
    • 4
  • Stefania Cuzzubbo
    • 2
    • 5
  • Jaime Gallego-Perez-Larraya
    • 1
    • 2
    • 7
  • Blandine Boisselier
    • 1
  • Francois Ducray
    • 1
  • Caroline Cheneau
    • 1
  • Arrigo Moglia
    • 3
  • Gaetano Finocchiaro
    • 5
  • Yannick Marie
    • 8
  • Amithys Rahimian
    • 1
    • 9
  • Khe Hoang-Xuan
    • 1
    • 2
  • Jean Yves Delattre
    • 1
    • 2
    • 9
  • Karima Mokhtari
    • 1
    • 9
    • 10
  • Marc Sanson
    • 1
    • 2
    • 9
    • 11
    Email author
  1. 1.UMPC Univ Paris VI, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, INSERM U 1127, CNRS, UMR 7225; GH Pitié-SalpêtrièrSorbonne UniversitésParisFrance
  2. 2.Service de Neurologie 2, AP-HPGroupe Hospitalier Pitié-SalpêtrièreParisFrance
  3. 3.National Neurological Institute C. Mondino, DBBSUniversity of PaviaPaviaItaly
  4. 4.Department of Experimental Oncology, Medical Oncology 1Veneto Institute of Oncology - IRCCSPaduaItaly
  5. 5.Neuro-oncology UnitNational Neurological Institute C. BestaMilanItaly
  6. 6.Deptartment RadiotherapyUniversity Hospital of PisaPisaItaly
  7. 7.Department of Neurology, Clinic of the University of NavarraUniversity of Navarra School of MedicinePamplonaSpain
  8. 8.Institut du Cerveau et de la Moelle épinière (ICM), Plateforme de Génotypage SéquençageParisFrance
  9. 9.OnconeurothèqueParisFrance
  10. 10.Laboratoire de Neuropathologie R. Escourolle, AP-HPGroupe Hospitalier Pitié-SalpêtrièreParisFrance
  11. 11.Service de Neurologie 2Groupe Hospitalier Pitié-SalpêtrièreParis Cedex 13France

Personalised recommendations